NO311920B1 - Xantinderivater som adenosin-A1-reseptorantagonister - Google Patents
Xantinderivater som adenosin-A1-reseptorantagonister Download PDFInfo
- Publication number
- NO311920B1 NO311920B1 NO19953353A NO953353A NO311920B1 NO 311920 B1 NO311920 B1 NO 311920B1 NO 19953353 A NO19953353 A NO 19953353A NO 953353 A NO953353 A NO 953353A NO 311920 B1 NO311920 B1 NO 311920B1
- Authority
- NO
- Norway
- Prior art keywords
- dipropyl
- purine
- dihydro
- dione
- give
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2350193A | 1993-02-26 | 1993-02-26 | |
| PCT/US1994/001009 WO1994019349A1 (en) | 1993-02-26 | 1994-01-27 | Xanthine derivatives as adenosine a1 receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO953353L NO953353L (no) | 1995-08-25 |
| NO953353D0 NO953353D0 (no) | 1995-08-25 |
| NO311920B1 true NO311920B1 (no) | 2002-02-18 |
Family
ID=21815459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19953353A NO311920B1 (no) | 1993-02-26 | 1995-08-25 | Xantinderivater som adenosin-A1-reseptorantagonister |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5840729A (OSRAM) |
| EP (1) | EP0686155B1 (OSRAM) |
| JP (1) | JPH08512281A (OSRAM) |
| KR (1) | KR100315898B1 (OSRAM) |
| CN (1) | CN1041418C (OSRAM) |
| AT (1) | ATE169019T1 (OSRAM) |
| AU (1) | AU680241B2 (OSRAM) |
| CA (1) | CA2155130C (OSRAM) |
| DE (1) | DE69412073T2 (OSRAM) |
| DK (1) | DK0686155T3 (OSRAM) |
| ES (1) | ES2120025T3 (OSRAM) |
| HU (1) | HUT72677A (OSRAM) |
| IL (1) | IL108750A (OSRAM) |
| MX (1) | MX9401406A (OSRAM) |
| NO (1) | NO311920B1 (OSRAM) |
| NZ (1) | NZ262984A (OSRAM) |
| TW (1) | TW261532B (OSRAM) |
| WO (1) | WO1994019349A1 (OSRAM) |
| ZA (1) | ZA941176B (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998041237A1 (en) * | 1997-03-18 | 1998-09-24 | Fujisawa Pharmaceutical Co., Ltd. | Preventives and remedies for hyperphosphatemia |
| WO1999062518A1 (en) | 1998-06-02 | 1999-12-09 | Osi Pharmaceuticals, Inc. | PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US20020115635A1 (en) * | 2001-02-21 | 2002-08-22 | Pnina Fishman | Modulation of GSK-3beta activity and its different uses |
| AU2002360436A1 (en) | 2001-11-30 | 2003-06-17 | Osi Pharmaceuticals, Inc. | 2-aryl pyrrologpyrimidines for a1 and a3 receptors |
| BR0215202A (pt) | 2001-12-20 | 2004-10-13 | Osi Pharm Inc | Compostos antagonistas seletivos a2b de pirimidina, sua sìntese e uso |
| US6875883B2 (en) * | 2002-05-15 | 2005-04-05 | Genzyme Corporation | Synthesis of benzonitriles from substituted benzaldehyde |
| WO2004086047A2 (en) * | 2003-03-28 | 2004-10-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a1 (adora1) |
| WO2005056016A1 (ja) * | 2003-12-09 | 2005-06-23 | Kyowa Hakko Kogyo Co., Ltd. | 高次脳機能障害の予防および／または治療剤 |
| US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7795427B2 (en) * | 2006-02-14 | 2010-09-14 | New York University | Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3843117A1 (de) * | 1988-12-22 | 1990-06-28 | Boehringer Ingelheim Kg | Neue xanthinderivate mit adenosin-antagonistischer wirkung |
| US5047534A (en) * | 1990-03-26 | 1991-09-10 | Merrell Dow Pharmaceuticals Inc. | Selective adenosine receptor agents |
| JPH0455150A (ja) * | 1990-06-22 | 1992-02-21 | Takata Kk | 助手席用エアバッグ装置 |
| DE4019892A1 (de) * | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
| US5087827A (en) * | 1991-02-11 | 1992-02-11 | Tektronix, Inc. | Variable voltage transition circuit |
| US5208240A (en) * | 1991-03-12 | 1993-05-04 | Merrell Dow Pharmaceuticals Inc. | 8-substituted purines as selective adenosine receptor agents |
| US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
-
1994
- 1994-01-27 AU AU62968/94A patent/AU680241B2/en not_active Ceased
- 1994-01-27 AT AT94910661T patent/ATE169019T1/de not_active IP Right Cessation
- 1994-01-27 KR KR1019950703577A patent/KR100315898B1/ko not_active Expired - Fee Related
- 1994-01-27 CA CA002155130A patent/CA2155130C/en not_active Expired - Fee Related
- 1994-01-27 NZ NZ262984A patent/NZ262984A/en unknown
- 1994-01-27 JP JP6518986A patent/JPH08512281A/ja active Pending
- 1994-01-27 HU HU9502495A patent/HUT72677A/hu unknown
- 1994-01-27 WO PCT/US1994/001009 patent/WO1994019349A1/en not_active Ceased
- 1994-01-27 EP EP94910661A patent/EP0686155B1/en not_active Expired - Lifetime
- 1994-01-27 US US08/500,991 patent/US5840729A/en not_active Expired - Fee Related
- 1994-01-27 CN CN94191309A patent/CN1041418C/zh not_active Expired - Fee Related
- 1994-01-27 DK DK94910661T patent/DK0686155T3/da active
- 1994-01-27 ES ES94910661T patent/ES2120025T3/es not_active Expired - Lifetime
- 1994-01-27 DE DE69412073T patent/DE69412073T2/de not_active Expired - Fee Related
- 1994-02-21 ZA ZA941176A patent/ZA941176B/xx unknown
- 1994-02-22 TW TW083101485A patent/TW261532B/zh active
- 1994-02-23 IL IL10875094A patent/IL108750A/xx not_active IP Right Cessation
- 1994-02-24 MX MX9401406A patent/MX9401406A/es not_active IP Right Cessation
-
1995
- 1995-08-25 NO NO19953353A patent/NO311920B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HUT72677A (en) | 1996-05-28 |
| ATE169019T1 (de) | 1998-08-15 |
| KR100315898B1 (ko) | 2002-02-28 |
| CA2155130A1 (en) | 1994-09-01 |
| DK0686155T3 (da) | 1999-02-01 |
| NO953353L (no) | 1995-08-25 |
| HU9502495D0 (en) | 1995-10-30 |
| WO1994019349A1 (en) | 1994-09-01 |
| EP0686155B1 (en) | 1998-07-29 |
| ES2120025T3 (es) | 1998-10-16 |
| IL108750A (en) | 2000-09-28 |
| AU6296894A (en) | 1994-09-14 |
| NZ262984A (en) | 1997-05-26 |
| JPH08512281A (ja) | 1996-12-24 |
| NO953353D0 (no) | 1995-08-25 |
| EP0686155A1 (en) | 1995-12-13 |
| ZA941176B (en) | 1994-09-20 |
| DE69412073T2 (de) | 1999-02-18 |
| AU680241B2 (en) | 1997-07-24 |
| MX9401406A (es) | 1994-08-31 |
| DE69412073D1 (de) | 1998-09-03 |
| TW261532B (OSRAM) | 1995-11-01 |
| US5840729A (en) | 1998-11-24 |
| CN1118599A (zh) | 1996-03-13 |
| CN1041418C (zh) | 1998-12-30 |
| IL108750A0 (en) | 1994-05-30 |
| CA2155130C (en) | 1994-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6545000B1 (en) | [1,2,4]triazolo[1,5-c]pyrimidine derivatives | |
| US5212176A (en) | R(+)-terazosin | |
| DK169271B1 (da) | 8-Phenylxanthinderivater, fremgansmåde til fremstilling heraf, farmaceutisk præparat indeholdende en sådan forbindelse, samt en sådan forbindelse til anvendelse til terapi | |
| DE69123974T2 (de) | Verbindungen welche antihypertensive und antiischemische eigenschaften besitzen | |
| RU2457842C2 (ru) | Способ предотвращения и лечения болезни печени с использованием антагонистов рецептора аденозина a2b | |
| DE69721776T2 (de) | Verbindungen mit antihypertensiven, cardioprotektiven, antiischämischen und antilipolytischen eigenschaften | |
| US20070208040A1 (en) | A2a adenosine receptor antagonists | |
| NO312679B1 (no) | N6 heterocykliske substituerte adenosinderivater, farmasöytisk sammensetning inneholdende samme, og anvendelse avsamme for fremstilling av preparat | |
| NO311920B1 (no) | Xantinderivater som adenosin-A1-reseptorantagonister | |
| EP1347981B1 (en) | Condensed purine derivatives as a 1 adenosine receptor antagonists | |
| AU2002219977A1 (en) | Condensed purine derivatives as A1 adenosine receptor antagonists | |
| US5047534A (en) | Selective adenosine receptor agents | |
| TW200817401A (en) | KW-3902 conjugates that do not cross the blood-brain barrier | |
| JPH08509977A (ja) | 選択的アデノシン受容体剤としての８−置換キサンチン類 | |
| JPWO2000017201A1 (ja) | ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体 | |
| HK1059927B (en) | Condensed purine derivatives as a1 adenosine receptor antagonists | |
| HK1038014A (en) | (1,2,4) TRIAZOLO(1,5-c) PYRIMIDINE DERIVATIVES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |